Case Report
Prolonged Recovery Time from Zoledronic Acid Induced Acute Tubular Necrosis: A Case Report and Review of the Literature
Table 2
Profile of reported cases of ARF associated with Zoledronic acid.
| Author | Case | Underlying disease | Baseline creatinine (mg/dL) | Bisphosphonate use prior to Zometa | Dose of Zometa (mg) | Recovery time (months) | Dialysis requirement (yes/no) | Serum creatinine peak/end (mg/dL) |
| Ramazzina et al. [1] | 1 | MM | U/K | Pamidronate × 4 doses | 4 mg | 9 | Yes | ESRD |
Markowitz et al. [2] | 2 | MM | 1.5 | Pamidronate × 13 doses | 4 mg | 4 | No | 4.0/2.4 | Markowitz et al. [2] | 3 | Paget’s | 1.5 | Pamidronate × 10 doses | 4 mg | 4 | No | 3.8/2.6 | Markowitz et al. [2] | 4 | MM | 1.3 | Pamidronate × 45 doses | 4 mg | 9 | No | 2.5/2.3 | Markowitz et al. [2] | 5 | MM | 1.4 | Pamidronate × 22 doses | 4 mg | 4 | No | 2.6/1.6 | Markowitz et al. [2] | 6 | MM | 1.5 | Pamidronate × 2 doses | 4 mg | 3 | No | 5.5/3.0 | Markowitz et al. [2] | 7 | Prostate Cancer | 1.0 | Pamidronate × 9 doses | 4 mg | 4 | No | 2.0/1.7 | Koike et al. [3] | 8 | MM | U/K | None | 4 mg | 7 | Yes | 7.3/UK | Joensuu [4] | 9 | Prostate Cancer | 0.7 | None | 4 mg | 5 | No | 1.2/0.7 | Our patient | 10 | Breast Cancer | 0.8 | None | 4 mg | >14 | No | 8.0/3.0 |
|
|
MM: multiple myeloma. ARF: acute renal failure.
|